logologo
CtrlK
logologo

Home

Watchlist

Market Screener

By Industry
Top Performing
Top Trading

Portfolio

News

News Feed
SEC Filings

Strategy Lab

Hedgefund
Community

Stocks

/

MRK

Merck & Co Inc

MRK

NYSE

Pharmaceuticals

$125.45

USD

+$5.25 (+4.37%)

Last close

Market Cap:

$303.70B

Volume:

13.9M

Price (USD)
Key Statistics

Previous Close

$120.20

Day Range

$121.00 - $125.96

52 Week Range

$76.66 - $125.14

Average Volume (10 Days)

13.2M

P/E Ratio

16.64

Dividend Yield

2.71%

About This Company

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

CEO

Mr. Robert Davis

Headquaters

Rahway, NEW JERSEY, US

Founded

1941

Employees

75,000

Latest News
Merck's Personalized mRNA Cancer Vaccine Shows Durable Melanoma Results

Merck and Moderna presented five-year follow-up data from their phase 2b trial showing that intismeran autogene, a personalized mRNA cancer vaccine combined with KEYTRUDA, reduced the risk of melanoma recurrence or death by 49% compared to KEYTRUDA alone in high-risk patients. The therapy has now advanced to phase 3 trials and demonstrated a manageable safety profile with no serious vaccine-related adverse events.

Quantli Newsdesk

•

21 days ago

•

MRK

0

0

Merck Beats Quarterly Estimates on Keytruda Strength, Narrows 2025 Outlook

Merck reported first-quarter sales of $16.29 billion, surpassing expectations on 12% growth from Keytruda. The company raised its full-year earnings guidance while navigating the 2028 patent expiration for its flagship cancer drug, which accounts for over half of pharmaceutical sales.

Similar Stocks

BMY

Bristol-Myers Squibb Co

$55.39

+0.1%

JNJ

Johnson & Johnson

$244.88

+1.8%

LLY

Eli Lilly and Co

$1127.69

+1.7%

ZTS

Zoetis Inc

$77.82

-0.5%

ELAN

Elanco Animal Health Inc

$24.37

+1.6%

Quantli Newsdesk

•

a month ago

•

MRK

0

0

PFE

Pfizer Inc

$23.67

-2.0%